Welcome to Bone Medical's homepage.

Expiry of Options
Click Here for Details

Appendix 3B – New issue announcement
Click Here for Details

Bone Medical lodges osteoporosis drug IND to US FDA
Click Here for Details

Appendix 3Z - Final Director’s Interest Notice
Click Here for Details

Board Restructure - CEO Resignation
Click Here for Details

Change of Interests of substantial Holder
Click Here for Details

Appendix 3B - New issue announcement
Click Here for Details

Results of General Meeting
Click Here for Details

Half Year Report
Click Here for Details

Positive FDA Feedback for CaPTHymone
Click Here for Details

Notice of General Meeting
Click Here for Details

Change of Interests of substantial Holding
Click Here for Details

Completion of Bone Medical private placement
Click Here for Details

Change of Interests of substantial Holding
Click Here for Details

Annual Report 2008
Click Here for Details

For a Complete List of Announcements:
Click Here

SEC Disclosures:
Click Here to View

        

 

 

.

 

 

 

 

 

                                               

 

.
Bone Medical Ltd (Bone) is focussed on breakthrough treatments for bone and joint degeneration and disease, especially osteoporosis and arthritis.

Our strategic aim is that:

Bone aims to be a leading global development based company in musculo-skeletal therapies by 2012

 

Bone Medical's Business Model

Bone’s business model is essentially simple and can be described as follows:

  • Outsourcing of non-essential functions;
  • Minimisation of organisational overheads;
  • Combine in-house development with academic collaborations to expand portfolio;
  • Out-licence products at points of development to maximise shareholder return;
  • Commitment to good corporate governance and scientific practices;
  • Reserve certain co-promotional rights where appropriate to build a future specialist sales capability; and
  • Use the global capital markets to finance progress